PD-MitoQUANT partner MIMETAS, the global leader in human-relevant organ-on-a-chip models, opened their new Phenotypic Screening Center on May 27, 2021. The center, located in Leiden, NL facilitates large-scale screening campaigns on Organ-on-a-Chip models, a powerful technology that improves the human physiological relevance of cultured tissues by utilizing microfluidic techniques. MIMETAS OrganoPlate® technology used in the PD-MitoQUANT project offers the scalability and the throughput needed for drug discovery studies.
“We are very proud to open up this new center,” said Jos Joore, CEO of MIMETAS. “Our new Phenotypic Screening Center facilitates high-throughput organ-on-a-chip screening combined with high-content imaging and machine learning data analysis to identify drug candidates for today’s unmet medical needs. Our customers understand that human-relevant disease models should be at the basis of every drug discovery effort. Moreover, these cutting-edge technologies stimulate the creativity and purpose of our scientists to make a difference in the lives of patients.”
The brand-new energy-neutral screening center is located in the new head office of MIMETAS at the shore of the Old Rhine, the ancient northern border of the Roman Empire. It is the first energy-neutral laboratory building in the Netherlands. This sustainable building has accomplished a 40% carbon dioxide reduction by reusing materials from a former Leiden University complex.
Read the official press release here.
This article was originally posted on: https://www.pdmitoquant.eu/2021/06/mimetas-opens-new-phenotypic-screening-center-in-leiden/